Literature DB >> 26674612

Individual risk alleles of susceptibility to schizophrenia are associated with poor clinical and social outcomes.

Shinji Sakamoto1, Manabu Takaki1, Yuko Okahisa1, Yutaka Mizuki1, Masatoshi Inagaki1, Hiroshi Ujike1, Toshiharu Mitsuhashi2, Soshi Takao3, Masashi Ikeda4, Yosuke Uchitomi1, Nakao Iwata4, Norihito Yamada1.   

Abstract

Many patients with schizophrenia have poor clinical and social outcomes. Some risk alleles closely related to the onset of schizophrenia have been reported to be associated with their clinical phenotypes, but the direct relationship between genetic vulnerability to schizophrenia and clinical/social outcomes of schizophrenia, as evaluated by both practical clinical scales and 'real-world' function, has not been investigated. We evaluated the clinical and social outcomes of 455 Japanese patients with schizophrenia by severity of illness according to the Clinical Global Impression-Severity Scale (CGI-S) and social outcomes by social adjustment/maladjustment at 5 years after the first visit. We examined whether 46 single nucleotide polymorphisms (SNPs) selected from a Japanese genome-wide association study of susceptibility to schizophrenia were associated with clinical and social outcomes. We also investigated the polygenic risk scores of 46 SNPs. Allele-wise association analysis detected three SNPs, including rs2623659 in the CUB and Sushi multiple domains-1 (CSMD1) gene, associated with severity of illness at end point. The severity of illness at end point was associated with treatment response, but not with the severity of illness at baseline. Three SNPs, including rs2294424 in the C6orf105 gene, were associated with social outcomes. Point estimates of odds ratios showed positive relationships between polygenic risk scores and clinical/social outcomes; however, the results were not statistically significant. Because these results are exploratory, we need to replicate them with a larger sample in a future study.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26674612     DOI: 10.1038/jhg.2015.153

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  44 in total

Review 1.  Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis.

Authors:  Diana O Perkins; Hongbin Gu; Kalina Boteva; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2005-10       Impact factor: 18.112

2.  The prognostic significance of early remission of positive symptoms in first treated psychosis.

Authors:  Ross M G Norman; Rahul Manchanda; Deborah Windell
Journal:  Psychiatry Res       Date:  2014-04-12       Impact factor: 3.222

3.  Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity.

Authors:  Satoko Miyatake; Hajime Touho; Noriko Miyake; Chihiro Ohba; Hiroshi Doi; Hirotomo Saitsu; Masataka Taguri; Satoshi Morita; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2012-08-30       Impact factor: 3.172

4.  The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia.

Authors:  Ryota Hashimoto; Kazutaka Ohi; Yuka Yasuda; Motoyuki Fukumoto; Masao Iwase; Naomi Iike; Michiyo Azechi; Koji Ikezawa; Masahiko Takaya; Hidetoshi Takahashi; Hidenaga Yamamori; Tomo Okochi; Hitoshi Tanimukai; Shinji Tagami; Takashi Morihara; Masayasu Okochi; Toshihisa Tanaka; Takashi Kudo; Hiroaki Kazui; Nakao Iwata; Masatoshi Takeda
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-10-18       Impact factor: 3.568

Review 5.  Clozapine: balancing safety with superior antipsychotic efficacy.

Authors:  Herbert Y Meltzer
Journal:  Clin Schizophr Relat Psychoses       Date:  2012-10

Review 6.  Schizophrenia.

Authors:  Kim T Mueser; Susan R McGurk
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

7.  CSMD1 is a novel multiple domain complement-regulatory protein highly expressed in the central nervous system and epithelial tissues.

Authors:  Damian M Kraus; Gary S Elliott; Hilary Chute; Thomas Horan; Karl H Pfenninger; Staci D Sanford; Stephen Foster; Sheila Scully; Andrew A Welcher; V Michael Holers
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

8.  Association between the duration of untreated psychosis and short- and long-term outcome in schizophrenia within the Northern Finland 1966 Birth Cohort.

Authors:  Matti Penttilä; Jouko Miettunen; Hannu Koponen; Merja Kyllönen; Juha Veijola; Matti Isohanni; Erika Jääskeläinen
Journal:  Schizophr Res       Date:  2012-11-22       Impact factor: 4.939

9.  Genome-wide association study identifies five new schizophrenia loci.

Authors: 
Journal:  Nat Genet       Date:  2011-09-18       Impact factor: 38.330

10.  Effects of the neurogranin variant rs12807809 on thalamocortical morphology in schizophrenia.

Authors:  Jamie Yu Jin Thong; Anqi Qiu; Min Yi Sum; Carissa Nadia Kuswanto; Ta Ahn Tuan; Gary Donohoe; Yih Yian Sitoh; Kang Sim
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

View more
  7 in total

Review 1.  The complement system in schizophrenia: where are we now and what's next?

Authors:  Julia J Woo; Jennie G Pouget; Clement C Zai; James L Kennedy
Journal:  Mol Psychiatry       Date:  2019-08-22       Impact factor: 15.992

2.  Association between depression in chronic phase and future clinical outcome of patients with schizophrenia.

Authors:  Yuto Yamada; Yusuke Yamauchi; Shinji Sakamoto; Masaki Fujiwara; Yuko Okahisa; Soshi Takao; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2022-02-21       Impact factor: 4.530

3.  Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.

Authors:  Yoshiaki Obayashi; Satoshi Mitsui; Shinji Sakamoto; Nozomu Minao; Bunta Yoshimura; Toshiki Kono; Yuji Yada; Yuko Okahisa; Soshi Takao; Yoshiki Kishi; Toshihiko Takeda; Manabu Takaki; Norihito Yamada
Journal:  Psychopharmacology (Berl)       Date:  2019-10-18       Impact factor: 4.530

4.  Csmd2 Is a Synaptic Transmembrane Protein that Interacts with PSD-95 and Is Required for Neuronal Maturation.

Authors:  Mark A Gutierrez; Brett E Dwyer; Santos J Franco
Journal:  eNeuro       Date:  2019-05-08

5.  Complex genetic dependencies among growth and neurological phenotypes in healthy children: Towards deciphering developmental mechanisms.

Authors:  Lisa Uechi; Mahjoubeh Jalali; Jayson D Wilbur; Jonathan L French; N L Jumbe; Michael J Meaney; Peter D Gluckman; Neerja Karnani; Nikita A Sakhanenko; David J Galas
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

6.  Genetic Variants in CSMD1 Gene Are Associated with Cognitive Performance in Normal Elderly Population.

Authors:  Vadim Stepanov; Andrey Marusin; Kseniya Vagaitseva; Anna Bocharova; Oksana Makeeva
Journal:  Genet Res Int       Date:  2017-12-12

7.  Perinatal Asphyxia in Rat Alters Expression of Novel Schizophrenia Risk Genes.

Authors:  Alessandra Paparelli; Keiko Iwata; Tomoyasu Wakuda; Conrad Iyegbe; Robin M Murray; Nori Takei
Journal:  Front Mol Neurosci       Date:  2017-10-27       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.